The results indicate Egfl7 as a novel and effective serological marker for the early detection of HCC with a better sensitivity and accuracy than AFP, which also could improve the efficacy of AFP, especially in the surveillance of a high-risk population with CLD and identification of the early HCC patients with negative AFP. This evidence concerns the gene EGFL7 and hepatocellular carcinoma.